Jean-Marie MICHOT | Medical Doctor | Institut de Cancérologie Gustave Roussy, Villejuif | IGR | Department of Hematology and Innovative Drugs | Research profile
Loop | Jean-Marie Michot
Novel oral agent with promising result as second-line treatment option for patients with T-Cell Lymphoma
Manageable safety profile and promising efficacy in heavily pretreated patients with R/R Non-Hodgin Lymphoma
Jean-Marie Michot | Lymphoma Hub
Jean-Marie Michot - Medical Oncologist - Gustave Roussy | LinkedIn
Jean-Marie MICHOT | Medical Doctor | Institut de Cancérologie Gustave Roussy, Villejuif | IGR | Department of Hematology and Innovative Drugs | Research profile
Jean-Marie Michot | EHA 2018 | What are the key safety and efficacy outcomes of the CC-122 and obinutuzumab study in R/R B-cell NHL?
Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-BASKET Study | JCO Precision Oncology
IMiD/Anti-CD20 combo induces complete responses in r/r NHL | MDedge Hematology and Oncology
Jean MICHOT | Institut de Cancérologie Gustave Roussy, Villejuif | IGR | Hematology | Research profile
Jean-Marie MICHOT | Medical Doctor | Institut de Cancérologie Gustave Roussy, Villejuif | IGR | Department of Hematology and Innovative Drugs | Research profile
General background Jean-Marie Michot
eha2018.hemato.net
J-M Michot (@MichotJM) / Twitter
Jean-Marie MICHOT | Medical Doctor | Institut de Cancérologie Gustave Roussy, Villejuif | IGR | Department of Hematology and Innovative Drugs | Research profile
Jean-Marie MICHOT | Medical Doctor | Institut de Cancérologie Gustave Roussy, Villejuif | IGR | Department of Hematology and Innovative Drugs | Research profile
Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/
Jean-Marie Michot - Medical Oncologist - Gustave Roussy | LinkedIn
Amazon.com: Jean-Marie Michot: Books, Biography, Blog, Audiobooks, Kindle
Jean-Marie MICHOT | Medical Doctor | Institut de Cancérologie Gustave Roussy, Villejuif | IGR | Department of Hematology and Innovative Drugs | Research profile
Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma by Pier Luigi Zinzani, Vincent. - ppt download
PDF) Successful Outcome of a Corticodependent Henoch-Schönlein Purpura Adult with Rituximab | Jean-françois Delfraissy - Academia.edu
Oncology in the Time of COVID-19: Quantitative Proteomic Analysis of Anti-IL6 Treated Patients - Biognosys
Video : Comment gérer la toxicité de l'immunothérapie ?
Management of toxicities related to immunotherapies
